Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
Contemporary Trends in the Nationwide Incidence of Primary Intracerebral Hemorrhage
Stroke 53:e70-e74, Bako, A.T.,et al, 2022
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Pregnancy, Hormonal Treatments for Infertility, Contraception, and Menopause in Women After Ischemic Stroke
Stroke 48:501-506, Caso, V.,et al, 2017
Community Based Case-Control Study of Childhood Stroke Risk Associated with Congenital Heart Disease
Stroke 46:336-340, Fox, C.K.,et al, 2015
Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia
NEJM 371:699-710, DeBaun, M.R.,et al, 2014
Stroke Recurrence in Children with Congenital Heart Disease
Ann Neurol 72:103-111, Rodan, L.,et al, 2012
Population-Based Study of Behavior Immediately After Transient Ischemic Attack and Minor Stroke in 1000 Consecutive Patients: Lessons for Public Education
Stroke 41:1108-1114, Chandratheva,A.,et al, 2010
Association Between Recent Sports Activity, Sports Activity in Young Adulthood, and Stroke
Stroke 40:425-431, Grau,A.J.,et al, 2009
Treatment of Childhood Arterial Ischemic Stroke
Ann Neurol 63:679-696, Bernard,T.J.,et al, 2008
Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke 39:2644-2691, Roach,E.S.,et al., 2008
Preeclampsia and the Risk of Ischemic Stroke Among Young Women
Stroke 37:1055-1059, Brown,D.W.,et al, 2006
Major Risk Factors for Intracerebral Hemorrhage in the Young Are Modifiable
Stroke 36:1881-1885, Feldmann,E.,et al, 2005
Discontinuing Prophylactic Transfusions Used to Preven Stroke in Sickle Cell Disease
NEJM 353:2769-2778,2743, The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators, 2005
Major Risk Factors for Aneurysmal Subarrachnoid Hemorrhage in the Young are Modifiable
Stroke 34:1375-1381, Broderick,J.P.,et al, 2003
Stroke Prevention and Treatment in Sickle Cell Disease
Arch Neurol 58:565-568, Adams,R.J., 2001
Cerebral Sinovenous Thrombosis in Children
NEJM 345:417-423, DeVeber,G.,et al, 2001
Silent Infarcts in Children With Sickle Cell Anemia and Abnormal Cerebral Artery Velocity
Arch Neurol 58:2017-2021, Pegelow,C.H.,et al, 2001
Prevent of a 1st Stroke by Transfusions in Children/Sickle Cell Anemia & Abnorm Results on Transcr Doppler Ultrasonog
NEJM 339:5-11, Adams,R.J.,et al, 1998
Surgical Closure of Patent Foramen Ovale in Cryptogenic Stroke Patients
Stroke 28:2376-2381, Homma,S.,et al, 1997
Discontinuation of Long-Term Transfusion Therapy in Patients with Sickle Cell Disease & Stroke
J Pediatr 131:757-760, Rana,S.,et al, 1997
Long-Term Stroke Risk in Children with Sickle Cell Disease Screened with Transcranial Doppler
Ann Neurol 42:699-704, Adams,R.J.,et al, 1997
Prognosis After Stroke Followed by Surgical Closure of Patent Foramen Ovale
Neurol 47:1162-1166, Devuyst,G.,et al, 1996
Time Course of Symptoms in Extracranial Carotid Artery Dissections:A Series of 80 Patients
Stroke 26:235-239, Biousse,V.,et al, 1995
Association Between Plasma Homocysteine Concentrations and Extracranial Carotid-Artery Stenosis
NEJM 332:286-291, 3281995., Selhub,J.,et al, 1995
Risk of Recurrent Stroke in Patients with Sickle Cell Disease Treated with Erythrocyte Transfusions
J Pediatr 126:896-899, Pegelow,C.H.,et al, 1995
Prospective Study of Endogenous Tissue Plasminogen Activator and Risk of Stroke
Lancet 343:940-943, Ridker,P.M.,et al, 1994
A Prospective Study of Cerebral Ischemia in the Young, Analysis of Pathogenic Determinants
Stroke 24:362-367, Carolei,A.,et al, 1993
Alcohol & Hemorrhagic Stroke, The Honolulu Heart Program
JAMA 255:2311-2314, Donahue,R.P.,et al, 1986
Familial Hyperlipidemia in Stroke in the Young
Stroke 17:1142-1145, Bansal,B.C.,et al, 1986